{
  "id": 8213908,
  "title": "Cue Biopharma stock initiated at Buy by B.Riley on allergy drug potential",
  "url": "https://urgent.news/2026/09/18/cue-biopharma-stock-initiated-at-buy-by-b-riley-on-allergy-drug",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-18T09:01:00.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/cue-biopharma-stock-initiated-at-buy-by-briley-on-allergy-drug-potential-93CH-4906841"
  },
  "original_language": "en",
  "account": "B.Riley has given Cue Biopharma Inc. (NASDAQ:CUE) a Buy rating and set a price goal of $83.00 per share. The company's stock price is currently $37.84, with a market capitalization of $274.89 million. Since last week, the stock has risen by 32% and climbed 313% year-to-date. In April 2026, Cue Biopharma appointed CEO Shao-Lee Lin, who founded Acelyrin and previously held positions at Horizon and AbbVie. Cue-221, an anti-IgE antibody, is the company's lead drug candidate, with proven effectiveness up to 313% in initial clinical trials. In a 15-patient study for chronic hives, the drug maintained undetectable free IgE levels for 14 weeks, while its price decreased over 100-fold. Another trial, involving 145 patients and controlled by Ascendant, is set to conclude by the third quarter of 2026. Investors should be aware that Cue Biopharma is currently using up its cash reserves, but it maintains a reasonable debt level. The company has around $67 million in pro forma cash following a $50 million financing round in July. The company is also set to start Phase 1 trials for CUE-401 by the end of this year. Cue Biopharma recently added Dominic Borie, M.D., Ph.D., as its Chief Medical Officer and Head of Research & Development. The company has also raised approximately $50 million through a private placement, issuing over 1.4 million shares and pre-funded warrants.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}